Calcium, calcium regulatory hormones, and calcimimetics: Impact on cardiovascular mortality

Journal of the American Society of Nephrology

Volumn 17, Issue SUPPL. 2, 2006, Pages

  Schmitt, Claus Peter ^a   Odenwald, Tobias ^a   Ritz, Eberhard ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Nierenzentrum   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIMIMETIC AGENT; CALCIUM; HORMONE; N [3 (2 CHLOROPHENYL)PROPYL] 1 (3 METHOXYPHENYL)ETHYLAMINE; PARATHYROID HORMONE; VITAMIN D;

BLOOD PRESSURE; BLOOD VESSEL CALCIFICATION; CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONFERENCE PAPER; DRUG EFFECT; DYSLIPIDEMIA; HEMODIALYSIS PATIENT; HUMAN; MORTALITY; NONHUMAN; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; RISK FACTOR; SECONDARY HYPERPARATHYROIDISM;

EID: 33645473650     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2005121338     Document Type: Conference Paper

References (38)

1. Raine AE, Margreiter R, Brunner FP, Ehrich JH, Geerlings W, Landais P, Loirat C, Mallick NP, Selwood NH, Tufveson G, et al: Report on management of renal failure in Europe, XXII, 1991. Nephrol Dial Transplant 7[Suppl 2]: 7-35, 1992
2. Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, Collins AJ: Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States medicare population, 1998 to 1999. J Am Soc Nephrol 16: 489-495, 2005
3. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium X phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31: 607-617, 1998
4. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK: Association of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12: 2131-2138, 2001
5. Moe SM, Chen NX: Pathophysiology of vascular calcification in chronic kidney disease. Circ Res 95: 560-567, 2004
6. Giachelli CM, Jono S, Shioi A, Nishizawa Y, Mori K, Morii H: Vascular calcification and inorganic phosphate. Am J Kidney Dis 38: S34-S37, 2001
7. Giachelli CM: Vascular calcification: In vitro evidence for the role of inorganic phosphate. J Am Soc Nephrol 14[Suppl 4]: S300-S304, 2003
8. Amann K, Tornig J, Kugel B, Gross ML, Tyralla K, El-Shakmak A, Szabo A, Ritz E: Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in experimental uremia. Kidney Int 63: 1296-1301, 2003
9. Stevens LA, Djurdjev O, Cardew S, Cameron EC, Levin A: Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: Evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol 15: 770-779, 2004
10. Block GA, Klassen FS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15: 2208-2218, 2004
11. Giachelli CM: Vascular calcification mechanisms. J Am Soc Nephrol 15: 2959-2964, 2004
12. Yang H, Curinga G, Giachelli CM: Elevated extracellular calcium levels induce smooth muscle cell matrix mineralization in vitro. Kidney Int 66: 2293-2299, 2004
13. Stefenelli T, Abela C, Frank H, Koller-Strametz J, Globits S, Bergler-Klein J, Niederle B: Cardiac abnormalities in patients with primary hyperparathyroidism: Implications for follow-up. J Clin Endocrinol Metab 82: 106-112, 1997
14. Hedback G, Oden A: Increased risk of death from primary hyperparathyroidism-An update. Eur J Clin Invest 28: 271-276, 1998
15. Hagstrom E, Lundgren E, Lithell H, Berglund L, Ljunghall S, Hellman P, Rastad J: Normalized dyslipidaemia after parathyroidectomy in mild primary hyperparathyroidism: Population-based study over five years. Clin Endocrinol (Oxf) 56: 253-260, 2002
16. Smogorzewski M, Perna AF, Borum PR, Massry SG: Fatty acid oxidation in the myocardium: Effects of parathyroid hormone and CRF. Kidney Int 34: 797-803, 1988
17. Baczynski R, Massry SG, Kohan R, Magott M, Saglikes Y, Brautbar N: Effect of parathyroid hormone on myocardial energy metabolism in the rat. Kidney Int 27: 718-725, 1985
18. Bogin E, Massry SG, Harary I: Effect of parathyroid hormone on rat heart cells. J Clin Invest 67: 1215-1227, 1981
19. Amann K, Ritz E, Wiest G, Klaus G, Mall G: A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. J Am Soc Nephrol 4: 1814-1819, 1994
20. Amann K, Tornig J, Flechtenmacher C, Nabokov A, Mall G, Ritz E: Blood-pressure-independent wall thickening of intramyocardial arterioles in experimental uraemia: Evidence for a permissive action of PTH. Nephrol Dial Transplant 10: 2043-2048, 1995
21. Massry SG, Goldstein DA: The search for uremic toxin(s) "X" "X" = PTH. Clin Nephrol 11: 181-189, 1979
22. Kestenbaum B, Andress DL, Schwartz SM, Gillen DL, Seliger SL, Jadav PR, Sherrard DJ, Stehman-Breen C: Survival following parathyroidectomy among United States dialysis patients. Kidney Int 66: 2010-2016, 2004
23. Foley RN, Li S, Liu J, Gilbertson DT, Chen SC, Collins AJ: The fall and rise of parathyroidectomy in US hemodialysis patients, 1992 to 2002. J Am Soc Nephrol 16: 210-218, 2005
24. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drueke TB, Goodman WG: Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350: 1516-1525, 2004
25. Wada M, Nagano N, Nemeth EF: The calcium receptor and calcimimetics. Curr Opin Nephrol Hypertens 8: 429-433, 1999
26. Hofer AM, Brown EM: Extracellular calcium sensing and signalling. Nat Rev Mol Cell Biol 4: 530-538, 2003
27. Ogata H, Ritz E, Odoni G, Amann K, Orth SR: Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors. J Am Soc Nephrol 14: 959-967, 2003
28. Ohanian J, Gatfield KM, Ward DT, Ohanian V: Evidence for a functional calcium-sensing receptor that modulates myogenic tone in rat subcutaneous small arteries. Am J Physiol Heart Circ Physiol 288: H1756-H1762, 2005
29. Jensen B, Farach-Carson MC, Kenaley E, Akanbi KA: High extracellular calcium attenuates adipogenesis in 3T3-L1 preadipocytes. Exp Cell Res 301: 280-292, 2004
30. Odenwald TRE, Roesch F, Schaefer F, Schmitt CP: The calcimimetic R568 lowers blood pressure, but not total body sodium content, in rats [Abstract]. J Am Soc Nephrol 15: 279a, 2004
31. Norman PE, Powell JT: Vitamin D, shedding light on the development of disease in peripheral arteries. Arterioscler Thromb Vasc Biol 25: 39-46, 2005
32. Holick MF: Sunlight and vitamin D: Both good for cardiovascular health. J Gen Intern Med 17: 733-735, 2002
33. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP: 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 110: 229-238, 2002
34. Chen S, Ni XP, Humphreys MH, Gardner DG: 1,25 Dihydroxyvitamin D amplifies type a natriuretic peptide receptor expression and activity in target cells. J Am Soc Nephrol 16: 329-339, 2005
35. Hass GM, Trueheart RE, Hemmens A: Experimental arteriosclerosis due to hypervitaminosis D. Am J Pathol 37: 521-549, 1960
36. Lamawansa MD, Wysocki SJ, House AK, Norman PE: Vitamin D3 exacerbates intimal hyperplasia in balloon-injured arteries. Br J Surg 83: 1101-1103, 1996
37. Rebsamen MC, Sun J, Norman AW, Liao JK: 1alpha,25-Dihydroxyvitamin D3 induces vascular smooth muscle cell migration via activation of phosphatidylinositol 3-kinase. Circ Res 91: 17-24, 2002
38. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R: Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349: 446-456, 2003